Article Figures & Data
Figures
- FIGURE 1.
Patient with recurrent GIST in stomach. (A) Transaxial 18F-FDG image (SUV image) at level of upper abdomen shows no significantly enhanced 18F-FDG uptake in stomach. (B) Corresponding transaxial bombesin image (SUV image) at level of upper abdomen shows enhanced bombesin uptake in stomach (SUV, 9.3).
- FIGURE 2.
(A) CT image of patient with metastatic GIST demonstrates soft-tissue mass medial to spleen. (B) Transaxial 18F-FDG image (SUV image) at level of CT image shows enhanced 18F-FDG uptake (SUV, 3.2) at location of CT finding. (C) Corresponding transaxial bombesin image (SUV image) at level of CT image shows slightly enhanced bombesin uptake (SUV, 2.0) at location of CT finding.
- FIGURE 3.
(Top left) Transaxial 18F-FDG image (SUV image) at level of liver demonstrates 2 hypermetabolic areas, one in ventral part of right liver lobe (SUV, 5.8) and another in stomach (SUV, 17.1), in patient with metastatic GIST. (Top right) CT image at same level demonstrates the 2 hypodense lesions in stomach and liver. (Bottom left) Transaxial bombesin image (SUV image) at level of CT image demonstrates clearly enhanced bombesin uptake only in liver lesion (SUV, 2.6). Bombesin uptake in stomach shows slight diffuse enhancement. (Bottom right) Fused image of 18F-FDG and bombesin transaxial slice shows an agreement for both tracers in the liver lesion, whereas the enhanced 18F-FDG uptake in the stomach is assigned to a low-bombesin-uptake area. Histology revealed recurrent stomach tumor and liver metastasis.
- FIGURE 4.
(A) Box-and-whisker plot of median SUV for both tracers 56–60 min after injection in malignant lesions. (B) Box-and-whisker plot of median values for both tracers for VB, k1, and k3 in malignant lesions.
Tables
Radiopharmaceutical Parameter Median Mean Minimum Maximum 18F-FDG k1 0.544 0.580 0.199 0.961 k2 0.803 0.780 0.500 0.999 k3 0.092 0.107 0.003 0.314 k4 0.003 0.006 0.000 0.023 VB 0.123 0.127 0.029 0.253 Fractal dimension 1.376 1.351 1.158 1.440 SUV 7.846 8.422 2.395 17.000 68Ga-BZH3 k1 0.500 0.500 0.377 0.612 k2 0.590 0.580 0.218 0.902 k3 0.022 0.047 0.000 0.189 k4 0.001 0.025 0.000 0.134 VB 0.188 0.231 0.050 0.588 Fractal dimension 1.214 1.160 0.870 1.400 SUV 3.270 3.270 0.536 9.253
Jump to section
Related Articles
Cited By...
- Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine
- Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study
- MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
- Bombesin-Targeted PET of Prostate Cancer
- "To Serve and Protect": Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting
- Radiopeptide Imaging and Therapy in Europe
- Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides
- Peptide-Based Probes for Cancer Imaging
- Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1
- International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States